The Emerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors publication covers some of the latest practice-changing advances as it relates to novel treatment strategies for patients with BRAF-mutated solid tumors.
February 22, 2022
Article
Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.
February 11, 2022
Video
Meredith McKean, MD, MPH, discusses the importance of molecular profiling in melanoma.
February 09, 2022
Article
Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.
February 03, 2022
Article
Developing BRAF inhibitors for patients with atypical class II and III mutations has become an exciting area of research.
January 31, 2022
Video
Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.
January 19, 2022
Video
Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.